FDA Panel Votes To Restrict GSK's Avandia
A divided U.S. Food and Drug Administration advisory committee voted Wednesday to keep GlaxoSmithKline PLC's troubled diabetes drug Avandia on the market, although nearly one-third of the panelists recommended that the...To view the full article, register now.
Already a subscriber? Click here to view full article